DXR insider grant vests: 2,344 shares added, total 17,616

Rhea-AI Filing Summary

Daxor Corp (DXR) reported an insider equity event by its Chief Medical Officer, John Jefferies. On November 12, 2025, he acquired 2,344 shares of Daxor common stock at a reported price of $0, coded as “P,” with the filing noting these shares were from a grant that vested on November 12, 2025.

Following this transaction, Jefferies beneficially owns 17,616 shares with direct ownership. The filing was made by one reporting person and identifies his role as Officer (Chief Medical Officer).

Insider Trade Summary

Net Buyer: 2,344 shares

Net Buy 1 txn

Insider Jefferies John

Role Chief Medical Officer

Bought 2,344 shs ($0.00)

Type	Security	Shares	Price	Value
Purchase	Daxor Common Stock	2,344	$0.00	$0.00

Holdings After Transaction: Daxor Common Stock — 17,616 shares (Direct)

Footnotes (1)

1. F1. 2,344 shares granted vest on November 12, 2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 11/14/2025 - 05:22 PM Learn about SEC filing dates

FAQ

What insider transaction did Daxor (DXR) disclose?

The Chief Medical Officer, John Jefferies, acquired 2,344 shares on November 12, 2025 at a reported price of $0.

How many Daxor (DXR) shares does the insider own after the transaction?

After the transaction, John Jefferies beneficially owns 17,616 shares, held directly.

What does the filing say about the nature of the 2,344 shares?

It states the 2,344 shares were from a grant that vested on November 12, 2025.

What is the insider’s role at Daxor (DXR)?

He is an Officer, serving as Chief Medical Officer.

Was this Form 4 filed by multiple reporting persons?

No. It was filed by one reporting person.

What was the transaction code reported?

The filing lists transaction code P for the acquisition.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jefferies John

(Last) (First) (Middle)

109 MECO LANE

(Street)

OAK RIDGE, TN 37830

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
DAXOR CORP [ DXR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
11/12/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Daxor Common Stock	11/12/2025		P		2,344(1)	A	$0	17,616	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. 2,344 shares granted vest on November 12, 2025.

	/s/ John Jefferies	11/14/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.